The type taxonomy of the H2 Antagonist market distinguishes between first‑generation compounds (cimetidine, ranitidine) and second‑generation agents (famotidine, nizatidine, roxatidine). First‑generation molecules, introduced in the 1970s, retain a modest share—approximately 25 % of global sales—due to legacy prescribing habits and lower acquisition cost, despite higher incidence of drug‑interaction warnings. Second‑generation agents dominate with roughly 75 % of revenue, benefiting from improved potency, reduced cytochrome‑P450 inhibition, and broader dosing flexibility. Within the second‑generation tier, oral tablets account for 80 % of volume, while injectable formulations, primarily used in intensive‑care prophylaxis, represent the remaining 20 %. This market taxonomy influences overall market size because pricing structures differ: first‑generation products are often generic and price‑compressed, whereas second‑generation brands command premium pricing and capture the majority of growth in emerging markets. Consequently, the shift toward newer, higher‑efficacy types drives the expansion of the H2 Antagonist market beyond the constraints of legacy drug‑supply chains. Regulatory scrutiny, especially after the ranitidine recall, has accelerated the migration to second‑generation products, reinforcing their share in both mature and developing economies.
